These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 29057215)

  • 1. Targeted Therapy for Medullary Thyroid Cancer: A Review.
    Priya SR; Dravid CS; Digumarti R; Dandekar M
    Front Oncol; 2017; 7():238. PubMed ID: 29057215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Overview of Medullary Thyroid Cancer Cases Treated at Kuwait Cancer Control Center.
    Shete J; AlSaleh K; Safwat R; Bedair A; ElSherify M; Hussein A; Nazeeh M; Mohanty A
    Gulf J Oncolog; 2020 Sep; 1(34):39-47. PubMed ID: 33431361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Updates on the Management of Medullary Thyroid Carcinoma.
    Kim BH; Kim IJ
    Endocrinol Metab (Seoul); 2016 Sep; 31(3):392-399. PubMed ID: 27586449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Putative BRAF activating fusion in a medullary thyroid cancer.
    Kasaian K; Wiseman SM; Walker BA; Schein JE; Hirst M; Moore RA; Mungall AJ; Marra MA; Jones SJ
    Cold Spring Harb Mol Case Stud; 2016 Mar; 2(2):a000729. PubMed ID: 27148585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective review of the multidisciplinary management of medullary thyroid cancer: eligibility for systemic therapy.
    Geller G; Laskin J; Cheung WY; Ho C
    Thyroid Res; 2017; 10():6. PubMed ID: 28932277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapies in thyroid cancer: an extensive review of the literature.
    Bikas A; Vachhani S; Jensen K; Vasko V; Burman KD
    Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1299-1313. PubMed ID: 27367142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Follow-up in Medullary Thyroid Carcinoma.
    Raue F; Frank-Raue K
    Recent Results Cancer Res; 2015; 204():207-25. PubMed ID: 26494391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating medullary thyroid cancer in the age of targeted therapy.
    Cabanillas ME; Hu MI; Jimenez C; Grubbs EG; Cote GJ
    Int J Endocr Oncol; 2014; 1(2):203-216. PubMed ID: 25908961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes.
    Fallahi P; Ferrari SM; Elia G; Ragusa F; Paparo SR; Ruffilli I; Patrizio A; Materazzi G; Antonelli A
    Cancer Manag Res; 2019; 11():7893-7907. PubMed ID: 31686907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Therapy in Thyroid Cancer: State of the Art.
    Valerio L; Pieruzzi L; Giani C; Agate L; Bottici V; Lorusso L; Cappagli V; Puleo L; Matrone A; Viola D; Romei C; Ciampi R; Molinaro E; Elisei R
    Clin Oncol (R Coll Radiol); 2017 May; 29(5):316-324. PubMed ID: 28318881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multikinase Inhibitors for the Treatment of Progressive, Metastatic Medullary Thyroid Cancer - An Evolving Paradigm.
    Jarzab B; Krajewska J
    Eur Endocrinol; 2014 Aug; 10(2):145-150. PubMed ID: 29872479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on the cytologic and molecular features of medullary thyroid carcinoma.
    Pusztaszeri MP; Bongiovanni M; Faquin WC
    Adv Anat Pathol; 2014 Jan; 21(1):26-35. PubMed ID: 24316908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New drugs for medullary thyroid cancer: new promises?
    Spitzweg C; Morris JC; Bible KC
    Endocr Relat Cancer; 2016 Jun; 23(6):R287-97. PubMed ID: 27185870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of pharmacotherapy options for the treatment of medullary thyroid cancer.
    Deshpande HA; Sheth K; Sosa JA; Roman S
    Clin Med Insights Oncol; 2012; 6():355-62. PubMed ID: 23133319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic Medullary Thyroid Carcinoma and Cabozantinib: Case Series and Review of Literature.
    Kapur S; Xiao H; Zakowski MF; Hameed MR; Levin MB
    World J Oncol; 2014 Apr; 5(2):81-89. PubMed ID: 29147383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Targeted Therapies of Aggressive Thyroid Cancer.
    Ferrari SM; Fallahi P; Politti U; Materazzi G; Baldini E; Ulisse S; Miccoli P; Antonelli A
    Front Endocrinol (Lausanne); 2015; 6():176. PubMed ID: 26635725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances and controversies in the management of medullary thyroid carcinoma.
    Maia AL; Wajner SM; Vargas CV
    Curr Opin Oncol; 2017 Jan; 29(1):25-32. PubMed ID: 27792051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenvatinib: Role in thyroid cancer and other solid tumors.
    Cabanillas ME; Habra MA
    Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines.
    Mitchell AL; Gandhi A; Scott-Coombes D; Perros P
    J Laryngol Otol; 2016 May; 130(S2):S150-S160. PubMed ID: 27841128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroid Gland Malignancies.
    Cabanillas ME; Dadu R; Hu MI; Lu C; Gunn GB; Grubbs EG; Lai SY; Williams MD
    Hematol Oncol Clin North Am; 2015 Dec; 29(6):1123-43. PubMed ID: 26568552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.